Partnering opportunities - Core Therapeutic Areas

We are looking for high-value, truly differentiating first or best-in-class treatments in:

  • Heart Failure, hypertension and atrial fibrillation
  • Atherosclerosis and multiple CV risk factor management
  • Metabolic (including obesity)
  • Autosomal dominant polycystic kidney disease (ADPKD)
  • Glomerular diseases (Alport, FSGS)
  • IgA nephropathy (IgAN)
Thierry Droz-Georget

Thierry Droz-Georget

Contact

  • Rheumatology
  • Dermatology
  • Disease modifying osteoarthiritis
  • Nucleic acid sensing & inflammasome
  • Tolerance induction
  • Allergy
Dominic Ehrismann

Dominic Ehrismann

Contact

  • MS and immuno-neurological diseases
  • Neurodegenerative diseases
  • Neuromuscular diseases
Chi-Chi Hhu

Chi-Chi Zhu

Contact

  • Breast cancers
  • Prostate cancers
  • Lung cancers
  • Colorectal and pancreatic cancers
  • Radioligand therapy (RLT): novel isotopes, chelators vectors and targets
  • Non-Hodgkin lymphoma (NHL)
  • Acute myeloid leukemia (AML)/ Myelodysplastic syndrome (MDS)
  • Multiple myeloma (MM)
  • Non-malignant hematology
Markus Werner

Markus Werner

Contact

Partnering opportunities - Technology Platforms

We are looking for innovative approaches to accelerate the development of therapeutics:

  • Artificial intelligence/Machine learning (AI/ML)
  • Synthesis and profiling automation
  • Novel approaches to accelerate discovery and synthesis of new molecular entities
  • Tissue targeting vectors for siRNA or Radioligand therapy (RLT)
  • Preclinical small molecule leads for innovative therapies
Avi Spier

Avi Spier

Contact

  • Novel approaches/platforms that leverage AI/ML and wet lab capabilities for challenging and multi-specific antibody discovery.
  • Targeted delivery and selective tropism to key tissues/cell types
  • Biodistribution, intracellular trafficking and stability assessment of Adeno-associated virus (AAV), Radioligand therapeutics (RLTs), and targeted siRNA conjugates
Gianfranco de Pascale

Gianfranco de Pascale

Contact

  • Novel T-cell-based therapy approaches for haematology & solid tumors
  • Approaches to reduce AAV immunogenicity
  • NextGen gene editing (non-viral)
  • Novel capsids with focus on CNS and Ophthalmology targeting
Markus Werner

Markus Werner (Oncology)

Contact

 

Elizabeth Leshen

Elizabeth Leshen (Rare diseases and neuroscience)

Contact

  • Targeted delivery approaches for RNA therapeutics to extra-hepatic tissues/cell types
  • Innovative siRNA chemistry platforms
  • In vivo/In vitro platforms to identify and validate siRNA targets
Gianfranco de Pascale

Gianfranco de Pascale

Contact

  • Discovery of new RLT binders (“vectors”)
  • Differentiated RLT assets that complement current pipeline and disease focus with novel isotopes, chelators or vectors for tumor specific RLT delivery
  • Explore various combination approaches which are synergistic with RLTs
Marcel Reichen

Marcel Reichen

Contact

Partnering opportunities - Other Areas

We have embarked on an ambitious transformation to become the leading medicines company powered by data science and digital technologies. Novartis partnering interests around AI platforms aim to:

  • Enable deeper understanding of disease
  • Power small and large molecule design
  • Increase predictive safety
  • Improve trial design
Cynthia Hong

Cynthia Hong

Contact

Interested in biomarker and diagnostic technologies that are designed to optimize the efficiency, safety and therapeutic benefit of our drugs. Technologies may include genomic and proteomic testing as well as artificial intelligence driven solutions.

Guy Greiveldinger

Guy Greiveldinger

Contact

 

Frank Dieterle

Frank Dieterle

Contact

Seeking partners such as NGOs, academic institutions, and companies to expand and accelerate our portfolio of drugs for neglected diseases, including emerging and tropical infectious diseases.

Charles Bailey

Charles Bailey

Contact

Novartis is open to discuss the sale of some commercial products in various geographies as well as to grant licenses to development stage compounds which have been de-prioritized for strategic reasons.

Sven Werner

Out licensing

Sven Werner

Contact

 

Business Man

Divestments

Jean Marc Séquier

Contact

Discover more